Clinical outcomes and survival in AA amyloidosis patients

Amyloid A amyloidosis is a rare complication of chronic inflammatory conditions. Most patients with amyloid A amyloidosis present with nephropathy and it leads to renal failure and death. We studied clinical characteristics and survival in patients with amyloid A amyloidosis. A total of 81 patients...

Full description

Saved in:
Bibliographic Details
Published in:Revista Brasileira de Reumatologia Vol. 57; no. 6; pp. 535 - 544
Main Authors: Ayar, Yavuz, Ersoy, Alparslan, Oksuz, Mustafa Ferhat, Ocakoglu, Gokhan, Vuruskan, Berna Aytac, Yildiz, Abdülmecit, Isiktas, Emel, Oruc, Aysegül, Celikci, Sedat, Arslan, Ismail, Sahin, Ahmet Bilgehan, Güllülü, Mustafa
Format: Journal Article
Language:English
Published: Brazil Sociedade Brasileira de Reumatologia 01-11-2017
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Amyloid A amyloidosis is a rare complication of chronic inflammatory conditions. Most patients with amyloid A amyloidosis present with nephropathy and it leads to renal failure and death. We studied clinical characteristics and survival in patients with amyloid A amyloidosis. A total of 81 patients (51 males, 30 females) with renal biopsy proven amyloid A amyloidosis were analyzed retrospectively. The patients were divided into good and poor outcomes groups according to survival results. Most of the patients (55.6%) had nephrotic range proteinuria at diagnosis. Most frequent underlying disorders were familial Mediterranean fever (21.2%) and rheumatoid arthritis (10.6%) in the good outcome group and malignancy (20%) in the poor outcome group. Only diastolic blood pressure in the good outcome group and phosphorus level in the poor outcome group was higher. Serum creatinine levels increased after treatment in both groups, while proteinuria in the good outcome group decreased. Increase in serum creatinine and decrease in estimated glomerular filtration rate of the poor outcome group were more significant in the good outcome group. At the time of diagnosis 18.5% and 27.2% of all patients had advanced chronic kidney disease (stage 4 and 5, respectively). Median duration of renal survival was 65±3.54 months. Among all patients, 27.1% were started dialysis treatment during the follow-up period and 7.4% of all patients underwent kidney transplantation. Higher levels of systolic blood pressure [hazard ratios 1.03, 95% confidence interval: 1-1.06, p=0.036], serum creatinine (hazard ratios 1.25, 95% confidence interval: 1.07-1.46, p=0.006) and urinary protein excretion (hazard ratios 1.08, 95% confidence interval: 1.01-1.16, p=0.027) were predictors of end-stage renal disease. Median survival of patients with organ involvement was 50.3±16 months. Our study indicated that familial Mediterranean fever constituted a large proportion of cases and increased number of patients with idiopathic amyloid A amyloidosis. Additionally, it was observed that patient survival was not affected by different etiological causes in amyloid A amyloidosis.
AbstractList Amyloid A amyloidosis is a rare complication of chronic inflammatory conditions. Most patients with amyloid A amyloidosis present with nephropathy and it leads to renal failure and death. We studied clinical characteristics and survival in patients with amyloid A amyloidosis. A total of 81 patients (51 males, 30 females) with renal biopsy proven amyloid A amyloidosis were analyzed retrospectively. The patients were divided into good and poor outcomes groups according to survival results. Most of the patients (55.6%) had nephrotic range proteinuria at diagnosis. Most frequent underlying disorders were familial Mediterranean fever (21.2%) and rheumatoid arthritis (10.6%) in the good outcome group and malignancy (20%) in the poor outcome group. Only diastolic blood pressure in the good outcome group and phosphorus level in the poor outcome group was higher. Serum creatinine levels increased after treatment in both groups, while proteinuria in the good outcome group decreased. Increase in serum creatinine and decrease in estimated glomerular filtration rate of the poor outcome group were more significant in the good outcome group. At the time of diagnosis 18.5% and 27.2% of all patients had advanced chronic kidney disease (stage 4 and 5, respectively). Median duration of renal survival was 65±3.54 months. Among all patients, 27.1% were started dialysis treatment during the follow-up period and 7.4% of all patients underwent kidney transplantation. Higher levels of systolic blood pressure [hazard ratios 1.03, 95% confidence interval: 1-1.06, p=0.036], serum creatinine (hazard ratios 1.25, 95% confidence interval: 1.07-1.46, p=0.006) and urinary protein excretion (hazard ratios 1.08, 95% confidence interval: 1.01-1.16, p=0.027) were predictors of end-stage renal disease. Median survival of patients with organ involvement was 50.3±16 months. Our study indicated that familial Mediterranean fever constituted a large proportion of cases and increased number of patients with idiopathic amyloid A amyloidosis. Additionally, it was observed that patient survival was not affected by different etiological causes in amyloid A amyloidosis.
Abstract Aim Amyloid A amyloidosis is a rare complication of chronic inflammatory conditions. Most patients with amyloid A amyloidosis present with nephropathy and it leads to renal failure and death. We studied clinical characteristics and survival in patients with amyloid A amyloidosis. Methods: A total of 81 patients (51 males, 30 females) with renal biopsy proven amyloid A amyloidosis were analyzed retrospectively. The patients were divided into good and poor outcomes groups according to survival results. Results: Most of the patients (55.6%) had nephrotic range proteinuria at diagnosis. Most frequent underlying disorders were familial Mediterranean fever (21.2%) and rheumatoid arthritis (10.6%) in the good outcome group and malignancy (20%) in the poor outcome group. Only diastolic blood pressure in the good outcome group and phosphorus level in the poor outcome group was higher. Serum creatinine levels increased after treatment in both groups, while proteinuria in the good outcome group decreased. Increase in serum creatinine and decrease in estimated glomerular filtration rate of the poor outcome group were more significant in the good outcome group. At the time of diagnosis 18.5% and 27.2% of all patients had advanced chronic kidney disease (stage 4 and 5, respectively). Median duration of renal survival was 65 ± 3.54 months. Among all patients, 27.1% were started dialysis treatment during the follow-up period and 7.4% of all patients underwent kidney transplantation. Higher levels of systolic blood pressure [hazard ratios 1.03, 95% confidence interval: 1-1.06, p = 0.036], serum creatinine (hazard ratios 1.25, 95% confidence interval: 1.07-1.46, p = 0.006) and urinary protein excretion (hazard ratios 1.08, 95% confidence interval: 1.01-1.16, p = 0.027) were predictors of end-stage renal disease. Median survival of patients with organ involvement was 50.3 ± 16 months. Conclusion Our study indicated that familial Mediterranean fever constituted a large proportion of cases and increased number of patients with idiopathic amyloid A amyloidosis. Additionally, it was observed that patient survival was not affected by different etiological causes in amyloid A amyloidosis.
Author Celikci, Sedat
Güllülü, Mustafa
Vuruskan, Berna Aytac
Oksuz, Mustafa Ferhat
Sahin, Ahmet Bilgehan
Yildiz, Abdülmecit
Ayar, Yavuz
Oruc, Aysegül
Ocakoglu, Gokhan
Arslan, Ismail
Isiktas, Emel
Ersoy, Alparslan
Author_xml – sequence: 1
  givenname: Yavuz
  surname: Ayar
  fullname: Ayar, Yavuz
  email: yavuzayar@hotmail.com
  organization: Uludağ University Faculty of Medicine, Department of Nephrology, Bursa, Turkey. Electronic address: yavuzayar@hotmail.com
– sequence: 2
  givenname: Alparslan
  surname: Ersoy
  fullname: Ersoy, Alparslan
  organization: Uludağ University Faculty of Medicine, Department of Nephrology, Bursa, Turkey
– sequence: 3
  givenname: Mustafa Ferhat
  surname: Oksuz
  fullname: Oksuz, Mustafa Ferhat
  organization: Uludağ University Medical Faculty, Department of Rheumatology, Bursa, Turkey
– sequence: 4
  givenname: Gokhan
  surname: Ocakoglu
  fullname: Ocakoglu, Gokhan
  organization: Uludağ University Medical Faculty, Department of Biostatistics, Bursa, Turkey
– sequence: 5
  givenname: Berna Aytac
  surname: Vuruskan
  fullname: Vuruskan, Berna Aytac
  organization: Uludağ University Medical Faculty, Department of Pathology, Bursa, Turkey
– sequence: 6
  givenname: Abdülmecit
  surname: Yildiz
  fullname: Yildiz, Abdülmecit
  organization: Uludağ University Faculty of Medicine, Department of Nephrology, Bursa, Turkey
– sequence: 7
  givenname: Emel
  surname: Isiktas
  fullname: Isiktas, Emel
  organization: Uludağ University Faculty of Medicine, Department of Nephrology, Bursa, Turkey
– sequence: 8
  givenname: Aysegül
  surname: Oruc
  fullname: Oruc, Aysegül
  organization: Uludağ University Faculty of Medicine, Department of Nephrology, Bursa, Turkey
– sequence: 9
  givenname: Sedat
  surname: Celikci
  fullname: Celikci, Sedat
  organization: Uludağ University Medical Faculty, Department of Internal Medicine, Bursa, Turkey
– sequence: 10
  givenname: Ismail
  surname: Arslan
  fullname: Arslan, Ismail
  organization: Uludağ University Medical Faculty, Department of Internal Medicine, Bursa, Turkey
– sequence: 11
  givenname: Ahmet Bilgehan
  surname: Sahin
  fullname: Sahin, Ahmet Bilgehan
  organization: Uludağ University Medical Faculty, Department of Internal Medicine, Bursa, Turkey
– sequence: 12
  givenname: Mustafa
  surname: Güllülü
  fullname: Güllülü, Mustafa
  organization: Uludağ University Faculty of Medicine, Department of Nephrology, Bursa, Turkey
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29173691$$D View this record in MEDLINE/PubMed
BookMark eNo90MlqwzAYBGBRUpo0zQv0UPwCdn9J1nYMoUsg0Et7Nr-1FAXbCpYTyNs3dDsNDMN3mFsyG9LgCbmnUFGg8nFfje3oKwZUVcAqAHZFFowJUQpgdEYWVIMpa6FgTlY57wEuy5oxDjdkzgxVXBq6IGbTxSFa7Ip0nGzqfS5wcEU-jqd4urRxKNbrAvtzl6JLOebigFP0w5TvyHXALvvVby7Jx_PT--a13L29bDfrXWm5llMprEQTgpIctTCqlgE8cs0URaa45joo5NY4r9E4U9eeWgkqWI8QUDPNl2T747qE--Ywxh7Hc5MwNt9FGj8bHKdoO9-0BjhTgnoqXC1qpz0LAoL0ktnWGHGxHn6sw7HtvfvX_v7gX1xqZIc
ContentType Journal Article
Copyright Copyright © 2017. Published by Elsevier Editora Ltda.
Copyright_xml – notice: Copyright © 2017. Published by Elsevier Editora Ltda.
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOA
DOI 10.1016/j.rbre.2017.02.002
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE

Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: http://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 2255-5021
EndPage 544
ExternalDocumentID oai_doaj_org_article_b9032751e15d454d8e2f50f6e62cb995
29173691
Genre Journal Article
Observational Study
GroupedDBID 0R~
0SF
4.4
457
6I.
AACTN
AAEDT
AAEDW
AAFTH
AAFWJ
AAIKJ
AALRI
AAXUO
ABMAC
ADBBV
ADEZE
ADVLN
AEXQZ
AGHFR
AITUG
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
CGR
CUY
CVF
EBS
ECM
EIF
EJD
FDB
IXB
KQ8
NCXOZ
NPM
ROL
SSZ
GROUPED_DOAJ
ID FETCH-LOGICAL-c386t-5c6a9ff763a859746f0ea38271a273838f7a3c9de8a9d944e1c607fcea0fa8283
IEDL.DBID DOA
ISSN 1809-4570
IngestDate Tue Oct 22 15:08:10 EDT 2024
Sat Sep 28 08:37:14 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Issue 6
Keywords Febre familiar do Mediterrâneo
Renal survival
Sobrevida renal
Doença renal crônica
Mortality
Mortalidade
AA amyloidosis
Chronic kidney disease
Familial Mediterranean fever
Amiloidose AA
Language English
License Copyright © 2017. Published by Elsevier Editora Ltda.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c386t-5c6a9ff763a859746f0ea38271a273838f7a3c9de8a9d944e1c607fcea0fa8283
OpenAccessLink https://doaj.org/article/b9032751e15d454d8e2f50f6e62cb995
PMID 29173691
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_b9032751e15d454d8e2f50f6e62cb995
pubmed_primary_29173691
PublicationCentury 2000
PublicationDate 2017-11-01
PublicationDateYYYYMMDD 2017-11-01
PublicationDate_xml – month: 11
  year: 2017
  text: 2017-11-01
  day: 01
PublicationDecade 2010
PublicationPlace Brazil
PublicationPlace_xml – name: Brazil
PublicationTitle Revista Brasileira de Reumatologia
PublicationTitleAlternate Rev Bras Reumatol Engl Ed
PublicationYear 2017
Publisher Sociedade Brasileira de Reumatologia
Publisher_xml – name: Sociedade Brasileira de Reumatologia
SSID ssj0001742230
Score 1.8077064
Snippet Amyloid A amyloidosis is a rare complication of chronic inflammatory conditions. Most patients with amyloid A amyloidosis present with nephropathy and it leads...
Abstract Aim Amyloid A amyloidosis is a rare complication of chronic inflammatory conditions. Most patients with amyloid A amyloidosis present with nephropathy...
SourceID doaj
pubmed
SourceType Open Website
Index Database
StartPage 535
SubjectTerms Adult
Aged
Aged, 80 and over
Amiloidose AA
Amyloidosis - complications
Amyloidosis - mortality
Amyloidosis - physiopathology
Creatinine - blood
Doença renal crônica
Familial Mediterranean Fever - complications
Familial Mediterranean Fever - mortality
Febre familiar do Mediterrâneo
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Mortalidade
Outcome Assessment (Health Care) - statistics & numerical data
Proportional Hazards Models
Proteinuria - urine
Renal Dialysis - statistics & numerical data
Renal Insufficiency, Chronic - etiology
Renal Insufficiency, Chronic - mortality
Renal Insufficiency, Chronic - physiopathology
Renal Insufficiency, Chronic - therapy
Retrospective Studies
Sobrevida renal
Young Adult
Title Clinical outcomes and survival in AA amyloidosis patients
URI https://www.ncbi.nlm.nih.gov/pubmed/29173691
https://doaj.org/article/b9032751e15d454d8e2f50f6e62cb995
Volume 57
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrZ27T8MwEMYt6MSCQLzKSx5YI-z4PZbSigUWQGKLnLMtVYIUNc3_jx1bHVhYWDJ4sOLPtnJfdPc7hO6cJtq2lFcAgkeDEkKlqTcVtBqMNsEbN7ZOeFUvH_pxkTA5u1ZfKScs44GzcPetIaxWgnoqHBfcaV8HQYL0sobWmEwvJTKbqeSudGqbJhQpFTI5mWsT_WXK41IZ0FkXQv-vWHL8piyP0GEJBvEsv8Qx2vPdCTIF1fmJ18M2ngff4-j2cT_ESx2PBV51eDbD9is67ZVb96seFzZqf4rel4u3-VNVGhxUwLTcVgKkTf9MJbM6BfYyEG-ZrhW1qWKG6aAsA-O8tsYZzj0FSVQAb0mw0SqxMzTp1p2_QBgsMQEYsVIwLgFaq7mjwE2qAPHAp-ghLbj5zgyLJlGlx4GodVO0bv7SeorOs1y7aero9pg09PI_pr9CB2mLcqXfNZpsN4O_Qfu9G27H3Y3Pxfz5B8v9qTo
link.rule.ids 315,782,786,866,2106,27933,27934
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+outcomes+and+survival+in+AA+amyloidosis+patients&rft.jtitle=Revista+Brasileira+de+Reumatologia&rft.au=Yavuz+Ayar&rft.au=Alparslan+Ersoy&rft.au=Mustafa+Ferhat+Oksuz&rft.au=Gokhan+Ocakoglu&rft.date=2017-11-01&rft.pub=Sociedade+Brasileira+de+Reumatologia&rft.issn=1809-4570&rft.volume=57&rft.issue=6&rft.spage=535&rft.epage=544&rft_id=info:doi/10.1016%2Fj.rbre.2017.02.002&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_b9032751e15d454d8e2f50f6e62cb995
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1809-4570&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1809-4570&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1809-4570&client=summon